Literature DB >> 11584986

Risperidone for the treatment of behavioral and psychological symptoms of dementia.

L E Tune1.   

Abstract

Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis. Numerous open-label and, more recently, placebo-controlled trials have documented the efficacy of risperidone in the management of behavioral and psychological symptoms of dementia. These trials also show that risperidone is better tolerated than conventional neuroleptic agents. Comparatively, patients treated with risperidone experience substantially fewer side effects, including extrapyramidal symptoms, cognitive toxicity, and tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584986

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  1 in total

1.  Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-11-26       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.